This is the first post for the Neurology Update blog. Neurology is our focus of interest and we follow the latest events in Neurology to help ourselves and readers stay tuned to the latest in Neurology.
We will start by talking about Multiple Sclerosis (MS). MS treatment is undergoing a period of change with a variety of new drugs likely to apply for approval with health authorities. Key ones include, Teriflunomide, Laquinimod, BG-12, Cladribine, PEG-Avonex, Lemtrada (a.k.a Campath), Ocrelizumab and Daclizumab. These are just few of the drugs in late testing stages which will file for approval over the next few years. Our effort on this blog will be track the development and response to these drugs over time and develop better understanding of these new therapies.
We will start by talking about Multiple Sclerosis (MS). MS treatment is undergoing a period of change with a variety of new drugs likely to apply for approval with health authorities. Key ones include, Teriflunomide, Laquinimod, BG-12, Cladribine, PEG-Avonex, Lemtrada (a.k.a Campath), Ocrelizumab and Daclizumab. These are just few of the drugs in late testing stages which will file for approval over the next few years. Our effort on this blog will be track the development and response to these drugs over time and develop better understanding of these new therapies.
No comments:
Post a Comment